One of the biggest barriers to early diagnosis and better treatments in LBD is the lack of a biomarker. Simply put, a biomarker is a biological test that confirms the presence (or progression) of a disease. Biomarkers can be used in a variety of ways, such as diagnosing a disorder, assessing the progression of a disease, or measuring the effects of a potential treatment in a clinical trial.
LBDA’s upcoming Ask the Expert webinar will feature three LBD researchers who are each studying LBD from different perspectives with the aim of identifying a biomarker. These exciting studies represent major new investments in LBD research by the National Institutes of Health as part of the strategy detailed in the National Plan to Address Alzheimer’s Disease (NAPA) and other dementias.